Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting

@article{Hengge2003DoubleblindRP,
  title={Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting},
  author={U. Hengge and K. Stocks and H. Wiehler and S. Faulkner and S. Esser and C. Lorenz and W. Jentzen and Dagmar Hengge and M. Goos and R. E. Dudley and G. Ringham},
  journal={AIDS},
  year={2003},
  volume={17},
  pages={699-710}
}
  • U. Hengge, K. Stocks, +8 authors G. Ringham
  • Published 2003
  • Medicine
  • AIDS
  • Background: Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients. Various alterations in energy metabolism and endocrine regulation have been found to cause loss of lean body mass (LBM) and body cell mass (BCM). Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of LBM, but these treatments have… CONTINUE READING
    Efficacy of Selected Treatments of HIV Wasting: A Systematic Review and Meta-Analysis
    • 17

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 63 REFERENCES
    Thalidomide for the treatment of AIDS-associated wasting.
    • 93
    Sustained anabolic effects of long-term androgen administration in men with AIDS wasting.
    • 47
    • PDF